influenza
viru
circul
among
human
five
epidem
wave
sinc
first
isol
china
recent
increas
infect
fifth
outbreak
china
caus
concern
possibl
pandem
studi
describ
previous
character
human
monoclon
antibodi
obtain
isol
rearrang
heavychain
lightchain
gene
patient
recov
infect
recogn
multipl
neutral
infect
strain
test
well
three
emerg
hpai
isol
resist
strain
carri
avian
receptor
allel
sialic
acidbind
pocket
mab
broadli
neutral
diverg
strain
repres
potenti
altern
treatment
intervent
influenza
viru
first
isol
southeastern
china
earli
sinc
five
epidem
wave
report
caus
human
infect
result
death
caus
sever
respiratori
distress
syndrom
patient
frequent
associ
secondari
bacteri
pneumonia
caus
multidrugresist
acinetobact
baumannii
klebsiella
pneumonia
notic
dysbiosi
oropharyng
microbiom
patient
also
observ
fifth
epidem
alon
human
infect
confirm
make
largest
epidem
date
although
sustain
humantohuman
transmiss
viru
confirm
limit
humantohuman
transmiss
observ
virus
abl
transmit
airborn
rout
ferret
infect
replic
human
lower
airway
potenti
effici
humantohuman
transmiss
increas
pandem
threat
furthermor
unlik
high
pathogen
avian
influenza
hpai
viru
caus
sever
diseas
bird
poultri
current
isol
virus
low
pathogen
avian
influenza
lpai
virus
typic
elicit
observ
sign
diseas
bird
viral
infect
earli
warn
diseas
control
pandem
may
extrem
difficult
although
hpai
virus
pathogen
bird
mammal
recent
emerg
case
spread
provinc
municip
mainland
china
due
abil
readili
transmit
bird
human
avianorigin
rais
concern
regard
potenti
increas
possibl
pandem
thu
prudent
conduct
clinic
trial
identifi
effect
treatment
influenza
typic
member
influenza
virus
classifi
subtyp
base
two
major
surfac
glycoprotein
haemagglutinin
ha
neuraminidas
na
respons
viral
recognit
attach
cellular
receptor
viral
releas
ha
na
ideal
target
antivir
drug
design
na
inhibitor
includ
oseltamivir
zanamivir
current
primari
therapeut
treatment
infect
clinic
set
howev
emerg
escap
mutant
resist
oseltamivir
zanamivir
even
altern
treatment
option
human
infect
urgent
need
vaccin
effect
intervent
season
influenza
demonstr
vaccin
abl
induc
product
neutral
nonneutr
antibodi
human
inactiv
vaccin
enter
clinic
trial
interest
encourag
discov
nonneutr
antibodi
could
also
protect
mice
infect
fcfcgr
interact
vaccin
season
strain
also
shown
elicit
crossreact
antibodi
although
level
serum
protect
gener
popul
remain
determin
howev
event
pandem
outbreak
massiv
vaccin
emerg
viru
promptli
achiev
herd
immun
limit
antivir
drug
resist
neutral
therapeut
antibodi
consid
potenti
effect
treatment
influenza
infect
passiv
immunotherapi
use
convalesc
plasma
patient
treat
infect
achiev
encourag
result
reduc
mortal
howev
largescal
product
antiserum
possibl
respons
emerg
epidem
product
neutral
monoclon
antibodi
mab
would
provid
feasibl
solut
problem
recent
studi
character
sever
neutral
antibodi
human
donor
target
differ
epitop
viral
ha
protein
repres
potenti
intervent
event
pandem
isol
lab
isol
rearrang
heavychain
lightchain
gene
human
survivor
recov
infect
antibodi
exhibit
potent
neutral
activ
influenza
vitro
vivo
studi
determin
breadth
effect
diverg
strain
isol
march
januari
well
three
hpai
variant
seri
repres
viral
isol
test
pseudovirusbas
neutral
assay
report
neutral
preval
strain
earli
isol
preval
strain
could
neutral
antibodi
trace
evolut
five
epidem
wave
randomli
select
ha
gene
human
virus
april
januari
conduct
polygenet
analys
shown
fig
result
confirm
human
descend
ancestor
similar
form
cluster
howev
initi
outbreak
broad
dissemin
viru
observ
indic
occurr
frequent
amino
acid
chang
ha
previous
report
antibodi
recogn
viral
receptor
bind
site
rb
evalu
potenti
antigen
drift
perform
align
randomli
select
sequenc
assess
amino
acid
substitut
viral
rb
shown
fig
mani
amino
acid
chang
occur
hypervari
region
around
receptorbind
pocket
determin
breadth
activ
bind
affin
test
panel
strain
test
fig
fail
bind
wherea
bound
strain
high
affin
k
valu
thu
mab
present
strikingli
strong
broad
bind
activ
suggest
broad
neutral
activ
diverg
strain
compar
five
amino
acid
substitut
occur
includ
assess
role
antigen
drift
viru
construct
five
mutant
carri
one
five
correspond
amino
acid
present
mutant
confirm
shown
fig
five
mutant
retain
abil
bind
nevertheless
mutat
led
notic
reduc
affin
dual
mutat
result
complet
loss
bind
mab
fig
contrast
revers
mutat
mutant
restor
abil
bind
fig
find
confirm
fulllength
viral
ha
mab
immobil
chip
seri
concentr
flow
immobil
mab
bind
affin
k
valu
calcul
use
steadyst
affin
model
produc
biacor
analysi
softwar
immunofluoresc
assay
ifa
detect
expect
ha
recogn
fig
mutat
disrupt
bind
ha
mab
wherea
bind
observ
introduc
ha
previous
shown
neutral
influenza
virus
cell
balbc
mice
studi
avoid
lethal
pathogen
live
viru
took
advantag
pseudovirusbas
neutral
assay
evalu
neutral
activ
pseudovirus
express
na
diverg
produc
cell
neutral
activ
test
suscept
mdck
cell
neutral
assay
live
virus
neutral
pseudoviru
dosedepend
manner
ic
ngml
fig
neutral
activ
diverg
strain
also
test
expect
although
strain
resist
antibodi
could
neutral
strain
estim
ic
valu
ngml
fig
mutat
led
antigen
drift
viral
fulllength
ha
protein
abil
mutat
confer
resist
mab
also
determin
c
mutat
restor
abil
mab
bind
ha
viral
ha
mutat
ha
protein
express
hela
cell
detect
via
ifa
use
pseudoviru
entri
assay
shown
fig
present
pseudoviru
success
escap
pressur
contrast
replac
mutat
neutral
mab
taken
togeth
result
confirm
respons
antigen
drift
neutral
emerg
hpai
strain
virus
remain
lpai
virus
poultri
sinc
first
appear
howev
human
infect
hpai
virus
report
februari
multibas
cleavag
site
motif
viral
ha
identifi
facilit
hpai
viru
replic
avian
speci
assess
neutral
activ
hpai
pseudovirus
express
ha
three
hpai
isol
na
gener
shown
fig
capabl
neutral
three
variant
ic
valu
ng
ml
avian
influenza
viru
continu
seriou
threat
public
health
rais
concern
potenti
pandem
thu
necessari
develop
vaccin
antivir
drug
well
neutral
antibodi
prevent
control
fatal
infect
human
present
studi
character
previous
isol
human
antibodi
determin
breadth
neutral
activ
signific
role
neutral
antibodi
protect
human
viral
infect
well
present
surfac
influenza
virion
ha
glycoprotein
primari
target
develop
neutral
antibodi
howev
high
variabl
viral
ha
make
difficult
develop
highli
crossreact
neutral
antibodi
especi
true
sinc
viral
ha
abl
continu
evolv
maintain
surfac
sialic
acid
receptor
bind
capabl
lead
escap
antibodi
respons
known
antigen
drift
although
differ
display
uniqu
structur
featur
sialic
acidbind
pocket
ha
rb
highli
conserv
recognit
common
receptor
rbsdirect
antibodi
success
achiev
modest
crossreact
interpos
smaller
footprint
receptor
bind
groov
howev
rbsdirect
antibodi
exhibit
limit
breadth
neutral
activ
includ
due
extra
contact
variabl
residu
peripheri
conserv
pocket
studi
test
bind
affin
differ
preval
strain
isol
april
januari
ha
rapidli
evolv
fig
consist
previou
result
ha
continu
mutat
high
rate
result
show
util
avid
extend
breadth
recognit
increas
affin
larg
portion
diverg
ha
strain
includ
variant
becom
domin
circul
strain
fifth
wave
exhibit
loss
bind
ha
variant
strain
earlier
isol
shanghai
epidem
carri
avian
signatur
prefer
avian
sialic
acid
cellular
receptor
rather
human
sialic
acid
receptor
limit
transmiss
human
strain
rare
observ
latter
outbreak
two
amino
acid
substitut
respons
prefer
differ
cellular
receptor
well
antigen
drift
fig
although
recogn
observ
bind
affin
complet
consist
approxim
tenfold
decreas
bind
affin
observ
carri
mutat
respect
indic
import
role
bind
reason
attenu
bind
affin
ajiangsu
remain
determin
howev
substitut
rb
four
strain
share
common
sure
worth
studi
pseudovirus
includ
three
emerg
hpai
isol
neutral
except
fig
howev
pseudotyp
viru
particl
entri
assay
may
overli
sensit
accur
assess
vitro
vivo
neutral
activ
use
live
virus
still
need
especi
necessari
sinc
mutat
gene
besid
ha
also
associ
viral
replic
capac
pathogen
transmiss
mutat
polymeras
basic
gene
enhanc
replic
mammal
mutat
identifi
hpai
strain
also
contribut
improv
replic
effici
togeth
na
mutat
confer
resist
oseltamivir
peramivir
nevertheless
base
genet
phylogenet
analys
recommend
may
serv
viabl
vaccin
candid
broad
protect
comprehens
survey
common
resist
mutat
among
mani
strain
test
suggest
mab
may
use
templat
therapeut
antibodi
genet
antigen
novel
influenza
viral
strain
continu
emerg
due
genet
natur
broad
host
rang
viru
absenc
effect
vaccin
direct
administr
antibodi
could
use
intervent
prevent
infect
human
approach
could
especi
help
high
risk
contract
administ
prophylact
confer
protect
virusinfect
mice
support
rational
altern
rbsdirect
neutral
antibodi
use
togeth
antivir
drug
eg
oseltamivir
zanamivir
control
product
escap
mutant
limit
effect
na
inhibitor
total
influenza
strain
isol
season
throughout
china
select
genet
character
retriev
fulllength
ha
amino
acid
sequenc
influenza
virus
align
refer
sequenc
avail
gisaid
databas
http
platformgisaidorg
clustalw
use
molecular
evolutionari
genet
analysi
mega
version
multipl
align
site
gap
sequenc
exclud
phylogenet
tree
gener
maximumlikelihood
method
bootstrap
replic
construct
phylogenet
tree
analyz
possibl
geograph
linkag
globular
head
protein
residu
base
number
express
use
bactobac
baculoviru
express
system
invitrogen
briefli
code
sequenc
amplifi
pcr
insert
pfastbaci
vector
invitrogen
facilit
protein
secret
purif
ntermin
signal
peptid
ctermin
histag
fuse
gene
recombin
bacmid
transfect
insect
cell
protein
purifi
nickelnitrilotriacet
acid
ninta
affin
chromatographi
follow
size
exclus
chromatographi
superdex
column
ge
health
care
ha
na
gene
stock
lab
remain
viral
gene
obtain
sitedirect
mutagenesi
rb
strain
accord
gene
align
result
fig
human
protein
mab
purifi
describ
previous
heavychain
lightchain
gene
clone
antibodi
express
vector
express
transient
transfect
cell
use
lipofectamin
invitrogen
cell
cultur
collect
h
later
centrifug
remov
cell
debri
human
protein
purifi
affin
chromatographi
use
protein
agaros
transgen
biotech
purifi
size
exclus
chromatographi
protein
concentr
measur
spectrophotometr
ge
healthcar
bind
viral
protein
measur
enzym
link
immunosorb
assay
elisa
plate
coat
overnight
viral
protein
ng
per
well
serial
fourfold
dilut
antibodi
begin
ng
pb
made
assay
bind
recombin
protein
wash
bound
antibodi
detect
horseradish
peroxidas
hrp
conjug
goat
antihuman
igg
ab
sigmaaldrich
nm
absorb
use
elisa
plate
reader
tecan
immunofluoresc
assay
ifa
perform
describ
previous
first
hela
cell
grown
glass
slide
monolay
next
pcdna
vector
express
ha
transfect
cell
use
lipofectamin
invitrogen
h
post
transfect
slide
fix
paraformaldehyd
wash
pb
cell
incub
h
bound
antibodi
detect
rhodamineconjug
goat
antihuman
igg
antibodi
invitrogen
observ
use
fluoresc
microscop
surfac
plasmon
reson
measur
perform
use
biacor
instrument
chip
ge
healthcar
room
temperatur
protein
exchang
pbst
buffer
phosphatebuff
salin
vv
ph
gel
filtrat
purifi
mab
first
immobil
chip
protein
serial
dilut
nm
nm
flow
mab
bind
kinet
analyz
biacor
analysi
softwar
biaevalu
version
use
langmuir
bind
model
gener
pseudovirus
viral
haand
naencod
sequenc
clone
pcdna
express
vector
cotransfect
backbon
plasmid
cell
use
lipofectamin
invitrogen
supernat
collect
h
transfect
pseudoviru
purifi
ultracentrifug
dissolv
phosphatebuff
salin
pb
store
aliquot
use
neutral
assay
obtain
sitedirect
mutagenesi
haencod
gene
accord
gene
align
result
fig
ha
gene
three
hpai
variant
includ
custom
synthes
clone
pcdna
vector
clone
use
confirm
sequenc
viral
titer
determin
mdck
cell
luciferas
activ
median
tissu
cultur
infect
dose
tcid
neutral
assay
perform
incub
tcid
pseudoviru
serial
dilut
antibodi
h
mixtur
ad
cultur
mdck
cell
viral
infect
quantifi
luciferas
activ
h
infect
irrelev
human
igg
protein
antihiv
immun
technolog
use
neg
control
